Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.
MYC is a transcription factor that plays relevant roles in cellular processes such as glycolysis, development, cell differentiation or proliferation. Recent research has associated the transcriptional activity of MYC to the activation of T cells in multiple sclerosis.
After a team at the Hospital Universitari Vall d’Hebron found that histone deacetylase 3 (HDAC3) has a role in the chronic inflammatory response in the central nervous system in models of traumatic brain injury, they investigated its role in autoimmune demyelination.
Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of patients with B-cell-driven neurologic autoimmune diseases, including multiple sclerosis and myasthenia gravis.
The differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes (OLs) promotes the remyelination in human brain. In multiple sclerosis (MS), dysfunctional OPC differentiation leads to remyelination failure and subsequent severe neurological disability.
High extracellular glutamate levels damage axons, myelin and oligodendrocytes in the context of inflammatory demyelinating disorders such as multiple sclerosis (MS).
To date, therapies for multiple sclerosis (MS) focus on modifying or suppressing the immune system rather than on remyelination. Recent findings have pointed to the κ-opioid receptor (KOR) as a therapeutic target for remyelination, but several KOR agonists have undesired side effects that limit their use. Researchers from the Victoria University of Wellington have tested KOR agonists derived from U-50488 in the preclinical setting for the management of MS.
The assessment of glycosylated autoantigens as immunotolerance therapies is emerging as a potential strategy for the treatment of several autoimmune diseases, such as type 1 diabetes, Crohn’s disease or multiple sclerosis.
Chimeric antigen receptor (CAR) T-cell therapy moved the needle at the 2024 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) congress and will continue to do so – not just in multiple sclerosis (MS), but in other autoimmune diseases as well.
